Suppr超能文献

减少门诊乳房重建手术后的阿片类药物处方量。

Reducing opioid prescribing after ambulatory breast reconstruction surgery.

作者信息

Fearon Nkechi J, Kurtzman Joey, Benfante Nicole, Assel Melissa, Vickers Andrew, Carlsson Sigrid, Laudone Vincent P, Levine Marcia, Simon Brett A, Mehrara Babak J, Nelson Jonas A

机构信息

Josie Robertson Surgical Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Department of Anesthesiology & Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

出版信息

J Surg Oncol. 2023 Dec;128(8):1235-1242. doi: 10.1002/jso.27427. Epub 2023 Aug 31.

Abstract

BACKGROUND

The lack of evidence-based guidelines for postoperative opioid prescriptions following breast reconstruction contributes to a wide variation in prescribing practices and increases potential for misuse and abuse.

METHODS

Between August and December 2019, women who underwent outpatient breast reconstruction were surveyed 7-10 days before (n = 97) and after (n = 101) implementing a standardized opioid prescription reduction initiative. We compared postoperative opioid use, pain control, and refills in both groups. Patient reported outcomes were compared using the BREAST-Q physical wellbeing of the chest domain and a novel symptom Recovery Tracker.

RESULTS

Before changes in prescriptions, patients were prescribed a median of 30 pills and consumed three pills (interquartile range [IQR: 1,9]). After standardization, patients were prescribed eight pills and consumed three pills (IQR: 1,6). There was no evidence of a difference in the proportion of patients experiencing moderate to very severe pain on the Recovery Tracker or in the early BREAST-Q physical wellbeing of the chest scores (p = 0.8 and 0.3, respectively).

CONCLUSION

Standardizing and reducing opioid prescriptions for patients undergoing reconstructive breast surgery is feasible and can significantly decrease the number of excess pills prescribed. The was no adverse impact on early physical wellbeing, although larger studies are needed to obtain further data.

摘要

背景

乳房重建术后阿片类药物处方缺乏循证指南,导致处方实践差异很大,并增加了滥用和误用的可能性。

方法

在2019年8月至12月期间,对接受门诊乳房重建的女性在实施标准化阿片类药物处方减量计划前7至10天(n = 97)和后(n = 101)进行了调查。我们比较了两组术后阿片类药物的使用、疼痛控制和续方情况。使用BREAST-Q胸部领域的身体健康量表和一个新的症状恢复追踪器对患者报告的结果进行了比较。

结果

在处方改变之前,患者的处方中位数为30片,服用了3片(四分位间距[IQR]:1,9)。标准化后,患者的处方为8片,服用了3片(IQR:1,6)。没有证据表明在恢复追踪器上经历中度至非常严重疼痛的患者比例或早期BREAST-Q胸部身体健康评分存在差异(p分别为0.8和0.3)。

结论

对接受乳房重建手术的患者进行阿片类药物处方的标准化和减量是可行的,并且可以显著减少过量处方的药片数量。尽管需要更大规模的研究来获取更多数据,但这对早期身体健康没有不利影响。

相似文献

5
Patterns of opioid use in dialysis access procedures.在透析通道建立手术中阿片类药物的使用模式。
J Vasc Surg. 2020 Sep;72(3):1018-1024. doi: 10.1016/j.jvs.2019.12.033. Epub 2020 Feb 27.
10
Changing Opioid Prescribing Algorithms in Plastic Surgery.整形外科中阿片类药物处方算法的改变
Ann Plast Surg. 2025 Apr 1;94(4S Suppl 2):S229-S232. doi: 10.1097/SAP.0000000000004215.

本文引用的文献

7
The Opioid Epidemic.阿片类药物流行。
Clin Plast Surg. 2020 Apr;47(2):181-190. doi: 10.1016/j.cps.2019.12.005.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验